Identifying Antidiabetic Drugs for Lung Cancer Treatment Through Genetic Epidemiology, Multiomics Integration, and Functional Validation
International Journal of Clinical Practice · 2026-01 · 2026 (1)
DOI: 10.1155/ijcp/1363193 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Practice, online erschienen am 12.08.2026. Verfasst von Yuzhu Chen und 6 weiteren Autor:innen. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Lung cancer remains the leading cause of cancer death globally, and metabolic conditions such as diabetes have been identified as important contributing risk factors. The overlapping biology between these diseases opens up opportunities for drug repositioning, yet the molecular mechanisms connecting antidiabetic drugs to lung cancer outcomes are not fully understood. This study aimed to identify repurposable antidiabetic medications for lung cancer by combining genetic epidemiology, multiomics profiling, and laboratory experiments, with the goal of uncovering clinically relevant biomarkers that could guide future patient selection and treatment strategies.
Methods
A two‐sample Mendelian randomization approach was used to evaluate causal relationships between cis‐expression quantitative trait loci from 35,684 individuals and lung cancer risk using genome‐wide association study summary data from the eQTLGen and TRICL consortia. Sensitivity analyses including heterogeneity testing, pleiotropy assessment, and leave‐one‐out validation were performed to ensure the robustness of the findings. Multi‐omics validation was then conducted, incorporating phenome‐wide association studies, functional enrichment analysis, protein–protein interaction network mapping, and somatic mutation profiling. In vitro experiments using A549 lung adenocarcinoma cells examined drug‐specific effects on cell migration and employed targeted gene knockdown to validate mechanistic pathways. The multidimensional dataset generated through this workflow is structured to support future machine learning applications for biomarker discovery and predictive modeling.
Results
Six medication target genes showed significant causal associations with lung cancer susceptibility. SERPINE1, PRKAB1, SLC29A1, and CCN3 emerged as protective factors, while CPT1A and INSR were identified as risk factors for lung cancer development. Multiomics characterization provided biological context for these genetic associations, revealing their involvement in metabolic regulation, inflammatory signaling, and cell cycle control pathways. Experimental work revealed divergent effects of antidiabetic drugs on lung cancer cell phenotype, with troglitazone inhibiting cell migration while glibenclamide stimulated migratory activity. Subsequent knockdown experiments established that SERPINE1 is required for maintaining the antimigratory effect of troglitazone, confirming its role as a key mechanistic mediator and a candidate response biomarker that could inform clinical decision making.
Conclusion
These findings support the development of biomarker‐driven clinical trials in lung cancer patients with metabolic comorbidities. The multidimensional dataset generated in this study also provides a foundation for applying machine learning methods to discover additional molecular signatures for patient stratification and treatment personalization.
Zitieren
APA
Chen, Y., Huang, X., Ou, J., Qi, F., Jiang, P., Zhang, T., & Cai, S. (2026). Identifying Antidiabetic Drugs for Lung Cancer Treatment Through Genetic Epidemiology, Multiomics Integration, and Functional Validation. International Journal of Clinical Practice, 2026(1). https://doi.org/10.1155/ijcp/1363193
Vancouver
Chen Y, Huang X, Ou J, Qi F, Jiang P, Zhang T, et al. Identifying Antidiabetic Drugs for Lung Cancer Treatment Through Genetic Epidemiology, Multiomics Integration, and Functional Validation. International Journal of Clinical Practice. 2026;2026(1). doi:10.1155/ijcp/1363193
BibTeX
@article{Chen2026,
author = {Chen, Yuzhu and Huang, Xin and Ou, Jiarui and Qi, Fei and Jiang, Peng and Zhang, Tongmei and Cai, Shanshan},
title = {Identifying Antidiabetic Drugs for Lung Cancer Treatment Through Genetic Epidemiology, Multiomics Integration, and Functional Validation},
journal = {International Journal of Clinical Practice},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/ijcp/1363193}
}
EUVIMED